Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
August 09, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference
August 07, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals Provides Business Highlights and Reports Second Quarter 2024 Financial Results
August 06, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)
June 28, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results
May 09, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
April 30, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ASX:CSL
CSLLY
SPRY
ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)
April 03, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day
March 07, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024
March 06, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study
February 26, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024
February 22, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter
February 20, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual Meeting
February 05, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 09, 2023
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis
November 09, 2023
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray)
October 06, 2023
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology
October 03, 2023
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
FDA Issues Complete Response Letter for neffy® (epinephrine nasal spray) New Drug Application with Request for Additional Study
September 19, 2023
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 10, 2023
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals Announces PDUFA Date Extension for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis
June 20, 2023
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results
May 15, 2023
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis
May 11, 2023
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on neffy® for the Treatment of Type I Allergic Reactions Including Anaphylaxis
May 09, 2023
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals Announces FDA Advisory Committee for neffy® for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis
March 28, 2023
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals Highlights Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
March 23, 2023
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors
February 23, 2023
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SBTX
SPRY
ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis
February 22, 2023
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SBTX
SPRY
ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023
February 09, 2023
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SBTX
SPRY
ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis
November 10, 2022
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SBTX
SPRY
ARS Pharmaceuticals Announces FDA Acceptance of NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) Including Anaphylaxis
October 21, 2022
From
ARS Pharmaceuticals, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.